| dc.contributor.author | Ronchi, C | |
| dc.contributor.author | Brisken, C | |
| dc.coverage.spatial | United States | |
| dc.date.accessioned | 2023-03-10T15:47:16Z | |
| dc.date.available | 2023-03-10T15:47:16Z | |
| dc.date.issued | 2022-12-22 | |
| dc.identifier | 711826 | |
| dc.identifier.citation | Clinical Cancer Research, 2022, pp. CCR-22-3374 - | en_US |
| dc.identifier.issn | 1078-0432 | |
| dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5722 | |
| dc.identifier.eissn | 1557-3265 | |
| dc.identifier.eissn | 1557-3265 | |
| dc.identifier.doi | 10.1158/1078-0432.CCR-22-3374 | |
| dc.identifier.doi | 10.1158/1078-0432.CCR-22-3374 | |
| dc.description.abstract | The pre-surgical window of opportunity trial (WOT), MIPRA, provides evidence that neoadjuvant treatment with the progesterone receptor (PR) antagonist Mifepristone (RU486) may benefit patients with ER+ breast cancer characterized by a high ratio of PR-A versus PR-B isoform (>1.5) suggesting that PR may be targeted in a subset of patients. | |
| dc.format | Print-Electronic | |
| dc.format.extent | CCR-22-3374 - | |
| dc.language | eng | |
| dc.language.iso | eng | en_US |
| dc.publisher | American Association for Cancer Research (AACR) | en_US |
| dc.relation.ispartof | Clinical Cancer Research | |
| dc.rights.uri | http://www.rioxx.net/licenses/all-rights-reserved | en_US |
| dc.title | Targeting the progesterone receptor in breast cancer: mind the short form! | en_US |
| dc.type | Journal Article | |
| dcterms.dateAccepted | 2022-12-22 | |
| dc.date.updated | 2023-03-10T15:46:11Z | |
| rioxxterms.version | AM | en_US |
| rioxxterms.versionofrecord | 10.1158/1078-0432.CCR-22-3374 | en_US |
| rioxxterms.licenseref.startdate | 2022-12-22 | |
| rioxxterms.type | Journal Article/Review | en_US |
| pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/36547665 | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrine control mechanisms | |
| pubs.publication-status | Published online | |
| pubs.publisher-url | http://dx.doi.org/10.1158/1078-0432.ccr-22-3374 | |
| icr.researchteam | Endocrine control mechans | en_US |
| dc.contributor.icrauthor | Brisken, Cathrin | |
| icr.provenance | Deposited by Mr Arek Surman on 2023-03-10. Deposit type is initial. No. of files: 1. Files: ccr-22-3374.pdf | |
